Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

Abstract

Coronaviruses can evolve and spread rapidly to cause severe disease morbidity and mortality, as exemplified by SARS-CoV-2 variants of the COVID-19 pandemic. Although currently available vaccines remain mostly effective against SARS-CoV-2 variants, additional treatment strategies are needed. Inhibitors that target essential viral enzymes, such as proteases and polymerases, represent key classes of antivirals. However, clinical use of antiviral therapies inevitably leads to emergence of drug resistance. In this study we implemented a strategy to pre-emptively address drug resistance to protease inhibitors targeting the main protease (M pro ) of SARS-CoV-2, an essential enzyme that promotes viral maturation. We solved nine high-resolution cocrystal structures of SARS-CoV-2 M pro bound to substrate peptides and six structures with cleavage products. These structures enabled us to define the substrate envelope of M pro , map the critical recognition elements, and identify evolutionarily vulnerable sites that may be susceptible to resistance mutations that would compromise binding of the newly developed M pro inhibitors. Our results suggest strategies for developing robust inhibitors against SARS-CoV-2 that will retain longer-lasting efficacy against this evolving viral pathogen.

References 58

1. 1.

   Ksiazek TG, et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953-1966.

   Not in our library10.1056/nejmoa030781 (opens in a new tab)

2. 2.

   Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814-1820.

   Not in our library10.1056/nejmoa1211721 (opens in a new tab)

3. 3.

   Brussow H, Brussow L. Clinical evidence that the pandemic from 1889 to 1891 commonly called the Russian flu might have been an earlier coronavirus pandemic. Micro. Biotechnol. 2021;14:1860-1870.

   Not in our library10.1111/1751-7915.13889 (opens in a new tab)

4. 4.

   Organization, W. H. COVID-19 vaccine tracker and landscape, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (2022).

   Not in our library

5. 5.

   Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603-2615.

   Not in our library10.1056/nejmoa2034577 (opens in a new tab)

6. 6.

   Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403-416.

   Not in our library10.1056/nejmoa2035389 (opens in a new tab)

7. 7.

   Li Y, et al. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent. Sci. 2021;7:512-533.

   Not in our library10.1021/acscentsci.1c00120 (opens in a new tab)

8. 8.
   SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses · 2022

   No notice
9. 9.

   Sievers, B. L. et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci. Transl. Med. 10.1126/scitranslmed.abn7842 (2022).

   Not in our library10.1126/scitranslmed.abn7842 (opens in a new tab)

10. 10.
    Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization · 2021

    No notice
11. 11.
    Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies · 2021

    No notice
12. 12.

    Cully M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nat. Rev. Drug Disco. 2022;21:3-5.

    Not in our library10.1038/d41573-021-00202-8 (opens in a new tab)

13. 13.
    Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential · 2021

    No notice
14. 14.

    Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med Chem. 2016;59:5172-5208.

    Not in our library10.1021/acs.jmedchem.5b01697 (opens in a new tab)

15. 15.

    Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. Molecular and dynamic mechanism underlying drug resistance in genotype 3 hepatitis C NS3/4A protease. J. Am. Chem. Soc. 2016;138:11850-11859.

    Not in our library10.1021/jacs.6b06454 (opens in a new tab)

16. 16.

    Matthew, A. N. et al. Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio11, 10.1128/mBio.00172-20 (2020).

    Not in our library10.1128/mbio.00172-20 (opens in a new tab)

17. 17.

    Ozen A, Prachanronarong K, Matthew AN, Soumana DI, Schiffer CA. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. Crit. Rev. Biochem Mol. Biol. 2019;54:11-26.

    Not in our library10.1080/10409238.2019.1568962 (opens in a new tab)

18. 18.

    Pennings PS. HIV drug resistance: problems and perspectives. Infect. Dis. Rep. 2013;5:e5.

    Not in our library10.4081/idr.2013.s1.e5 (opens in a new tab)

19. 19.

    Robinson M, Tian Y, Delaney WET, Greenstein AE. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc. Natl Acad. Sci. USA. 2011;108:10290-10295.

    Not in our library10.1073/pnas.1101515108 (opens in a new tab)

20. 20.

    Lampejo T. Influenza and antiviral resistance: an overview. Eur. J. Clin. Microbiol Infect. Dis. 2020;39:1201-1208.

    Not in our library10.1007/s10096-020-03840-9 (opens in a new tab)

21. 21.
    Systematic review of influenza resistance to the neuraminidase inhibitors · 2011

    No notice
22. 22.

    Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving viral protease inhibitors to counter drug resistance. Trends Microbiol. 2016;24:547-557.

    Not in our library10.1016/j.tim.2016.03.010 (opens in a new tab)

23. 23.

    Hertogs K, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 2000;14:1203-1210.

    Not in our library10.1097/00002030-200006160-00018 (opens in a new tab)

24. 24.

    Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 2011;55:192-206.

    Not in our library10.1016/j.jhep.2011.01.011 (opens in a new tab)

25. 25.

    Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure. 2002;10:369-381.

    Not in our library10.1016/s0969-2126(02)00720-7 (opens in a new tab)

26. 26.
    The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors · 2012

    No notice
27. 27.

    Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl Acad. Sci. USA. 2010;107:20986-20991.

    Not in our library10.1073/pnas.1006370107 (opens in a new tab)

28. 28.
    Molecular Basis for Drug Resistance in HIV-1 Protease · 2010

    No notice
29. 29.
    Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography · 2020

    No notice
30. 30.

    Ebrahim, A. et al. The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M (pro)). 10.1101/2021.05.03.437411 (2021).

    Not in our library10.1107/s2052252522007497 (opens in a new tab)

31. 31.
    Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors · 2020

    No notice
32. 32.

    Jin Z, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289-293.

    Not in our library10.1038/s41586-020-2223-y (opens in a new tab)

33. 33.
    Only One Protomer Is Active in the Dimer of SARS 3C-like Proteinase · 2006

    No notice
34. 34.

    Flynn, J. M. et al. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. bioRxiv 2022.01.26.477860; 10.1101/2022.01.26.477860 (2022).

    Not in our library10.7554/elife.77433 (opens in a new tab)

35. 35.

    Romano KP, et al. Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. J. Virol. 2011;85:6106-6116.

    Not in our library10.1128/jvi.00377-11 (opens in a new tab)

36. 36.

    MacDonald EA, et al. Recognition of divergent viral substrates by the SARS-CoV-2 main protease. ACS Infect. Dis. 2021;7:2591-2595.

    Not in our library10.1021/acsinfecdis.1c00237 (opens in a new tab)

37. 37.

    Nageswara Rao D, et al. Discovery of quinoxaline-based P1-P3 macrocyclic NS3/4A protease inhibitors with potent activity against drug-resistant hepatitis C virus variants. J. Med Chem. 2021;64:11972-11989.

    Not in our library10.1021/acs.jmedchem.1c00554 (opens in a new tab)

38. 38.

    Zhao XZ, et al. Structure-guided optimization of HIV integrase strand transfer inhibitors. J. Med Chem. 2017;60:7315-7332.

    Not in our library10.1021/acs.jmedchem.7b00596 (opens in a new tab)

39. 39.

    Passos DO, et al. Structural basis for strand-transfer inhibitor binding to HIV intasomes. Science. 2020;367:810-814.

    Not in our library10.1126/science.aay8015 (opens in a new tab)

40. 40.

    Chitnumsub P, et al. The structure of Plasmodium falciparum hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase reveals the basis of sulfa resistance. FEBS J. 2020;287:3273-3297.

    Not in our library10.1111/febs.15196 (opens in a new tab)

41. 41.

    Owen DR, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586-1593.

    Not in our library10.1126/science.abl4784 (opens in a new tab)

42. 42.

    Hoffman RL, et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med Chem. 2020;63:12725-12747.

    Not in our library10.1021/acs.jmedchem.0c01063 (opens in a new tab)

43. 43.

    Zhang CH, et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent. Sci. 2021;7:467-475.

    Not in our library10.1021/acscentsci.1c00039 (opens in a new tab)

44. 44.

    Zaidman D, et al. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 M(pro) inhibitor. Cell Chem. Biol. 2021;28:1795-1806 e1795.

    Not in our library10.1016/j.chembiol.2021.05.018 (opens in a new tab)

45. 45.
    Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease · 2020

    No notice
46. 46.

    Namchuk MN. Early returns on small molecule therapeutics for SARS-CoV-2. ACS Infect. Dis. 2021;7:1298-1302.

    Not in our library10.1021/acsinfecdis.0c00874 (opens in a new tab)

47. 47.

    Lockbaum, G. J. et al. Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses13, 10.3390/v13020174 (2021).

    Not in our library10.3390/v13020174 (opens in a new tab)

48. 48.

    Lockbaum GJ, et al. Pan-3C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode. Biochemistry. 2021;60:2925-2931.

    Not in our library10.1021/acs.biochem.1c00414 (opens in a new tab)

49. 49.
    XDS · 2010

    No notice
50. 50.
    Phaser crystallographic software · 2007

    No notice
51. 51.

    Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr. 2004;60:2126-2132.

    Not in our library10.1107/s0907444904019158 (opens in a new tab)

52. 52.
    PHENIX : a comprehensive Python-based system for macromolecular structure solution · 2010

    No notice
53. 53.

    Brunger AT. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 1992;355:472-475.

    Not in our library10.1038/355472a0 (opens in a new tab)

54. 54.

    Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput Aided Mol. Des. 2013;27:221-234.

    Not in our library10.1007/s10822-013-9644-8 (opens in a new tab)

55. 55.

    Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996;118:11225-11236.

    Not in our library10.1021/ja9621760 (opens in a new tab)

56. 56.

    Ali A, et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 2013;8:1469-1478.

    Not in our library10.1021/cb400100g (opens in a new tab)

57. 57.

    Nalam MN, et al. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 2010;84:5368-5378.

    Not in our library10.1128/jvi.02531-09 (opens in a new tab)

58. 58.

    Hunter J. Matplotlib is a 2D graphics package used for Python for application development, interactive scripting,and publication-quality image generation across user interfaces and operating systems. Comput. Sci. Eng. 2007;9:90-95.

    Not in our library10.1109/mcse.2007.55 (opens in a new tab)

Cited by papers we hold 2

• The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII · 2025
  Not checked
• Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir · 2023
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.